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Screening for disease with computed tomography (CT) is
fast becoming an enterprise. Whole-body CT screening is
heavily marketed in the US, and while marketing direct-
ed toward the European population is less aggressive, the
interest is no less. Direct consumer advertisement reach-
es out to the “worried wealthy” individual, who is usual-
ly healthy! CT screening is advertised on billboards, in
newspapers, on television, and through the Internet.
Selective information, astute framing of the data, and
subliminal messages lure the individual to undergo a
scan. Health care consumers are increasingly well
informed due to modern information technology and, as
a result, are demanding high-technology health care. CT
screening addresses the main killers of the Western world:
coronary heart disease (CHD), lung cancer, and colorec-
tal cancer. In addition, abdominal aortic aneurysms
(AAAs) are easily detected with CT. Abdominal tumors,
other than colorectal cancer, may also be detected with
CT. Powerful anecdotes that favor screening abound.
Employer, peer, and family pressure may also influence
an individual to undergo CT screening in the absence of
symptoms that would normally warrant investigation.
But where is the evidence that screening with CT does
more good than harm? This evidence is lacking. Cur-
rently, no large-scale randomized controlled trials
(RCTs) of screening with CT are published in the litera-
ture. The cost-effectiveness analyses published thus far
that evaluate screening with CT are generally based on
sparse data and questionable assumptions. Published
cohort studies provide some evidence of diagnostic and
prognostic value, but that is not enough to support the
large-scale use of CT screening of ostensibly healthy indi-
viduals. The trade-offs need to be clarified. As yet, it is
not clear that true-positive findings lead to gains in life
expectancy and quality of life. Furthermore, for some
diseases, the large proportion of false-positive results
and the risks, anxiety, and costs associated with the fur-
ther diagnostic workup required argue strongly against
screening. Recently, powerful anecdotes have illustrated
the potential pitfalls of CT screening, particularly the
high number of false-positive test results and their con-
sequences (1). Furthermore, whereas the consumer sees
only the out-of-pocket expense for the screening exami-
nation (often paid by the firm where he or she is
employed), the follow-up diagnostic tests and treatment
costs are paid for by medical insurance companies and
Medicare or Medicaid, the effect of which will ultimate-
ly be reflected in a national increase in health insurance
premiums and taxes. Finally, although the risk associat-
ed with exposure to radiation during a one-time scan is
low, if CT scanning were to be repeated regularly, the
cumulative radiation dose could become a significant
risk. Given these uncertainties and risks, various profes-
sional societies have placed statements on their websites
cautioning against CT screening.
The purpose of this review is to illustrate the trade-
offs involved in screening with CT. We consider four
diseases that can be diagnosed with CT: coronary
artery disease, lung cancer, colorectal cancer, and
AAAs. For each of these diseases a different CT exami-
nation is performed: multidetector row CT (MDCT) or
electron-beam CT (EBCT) scan, designed to measure
coronary calcification; helical lung CT; CT colonogra-
phy; and abdominal CT scan, respectively. We will first
discuss some general guidelines that indicate when
screening is warranted, the impact of false-positive
outcomes as they relate to scan sensitivity and speci-
ficity, the impact of significant secondary findings, the
predicted benefit of screening in terms of life years
gained, and the financial commitment. We will subse-
quently discuss each of the four diseases specifically in
the context of these issues.
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True- and false-positive and true- and 
false-negative test outcomes
The most common and most desired outcome of
screening is a true-negative outcome (i.e., true normal
findings): the individual is healthy and reassured and
quality of life may be positively affected (although the
effect is generally short-lived). An individual with a
true-negative outcome may in the future, however,
interpret the normal finding as an argument against
the presence of disease, implying that he or she may
ignore signs and symptoms of early disease, which may
subsequently develop. In addition, after a true-negative
outcome, individuals may mistakenly believe that other
well-established medical examinations such as pap
smears are unnecessary. Furthermore, a true-negative
outcome may be interpreted as sanctioning an
unhealthy lifestyle, which would not be beneficial to
the individual and may cause disease in the future.
A false-negative outcome (i.e., false normal findings)
would give the individual false reassurance, and he or
she may ignore signs and symptoms of early disease,
which would cause a delay in diagnosis and treatment.
Furthermore, normal findings may be interpreted as
sanctioning an unhealthy lifestyle and may make other
medical examinations seem unnecessary even though
the individual is at increased risk.
False-positive outcomes (i.e., false abnormal findings,
including lesions that are innocuous, such as cysts,
hemangiomas, and masses that result from past infec-
tions) lead to further diagnostic workup and possibly
even treatment. This may involve follow-up examina-
tions to evaluate the lesion for progression, a CT or
MRI examination with intravenous injection of con-
trast medium to study the characteristics of the lesion,
percutaneous or open biopsies, intraarterial angiogra-
phy, percutaneous therapeutic procedures, diagnostic
wedge resections, or surgery. These procedures are asso-
ciated with mortality and morbidity, anxiety, lost pro-
ductivity, and medical and nonmedical costs. The pro-
portion and consequences of false-positive outcomes
generally drive the balance among risks, benefits, and
costs in screening decisions.
True-positive outcomes (i.e., true abnormal findings)
should lead to a real gain in order to make screening
effective. It is assumed that, regarding detection of the
disease, “earlier is better.” With respect to atheroscle-
rotic disease, the “body visualization” of subclinical car-
diovascular disease can motivate lifestyle changes, risk
factor management, and preventive medical therapy.
Such actions may prevent more serious manifestations
of cardiovascular disease such as myocardial infarction
(MI) or stroke. With respect to cancer, “earlier is better”
assumes that diagnosis of precancerous lesions or can-
cer in an early, localized stage will lead to survival bene-
fit. For example, colorectal polyps are precancerous
lesions that, if left untreated, may progress to colorectal
cancer. Reported gains in survival by diagnosis of can-
cers in an early stage may, however, be biased in several
ways, as may the reports on survival gains with the
treatment of subclinical cardiovascular disease. The
apparent gain may be due to lead-time bias (earlier
detection and therefore a longer period in which disease
is known but there is no survival advantage), overdiag-
nosis/pseudodisease (detection of clinically irrelevant
disease), length bias (preferential detection of very slow-
ly progressing disease), and/or pseudo–stage shift bias
(advanced disease-stage shifted to early stage but with-
in this stage a more aggressive tumor or, in the case of
atherosclerosis, a vulnerable plaque).
The combination of prevalence of disease, sensitivi-
ty, and specificity determines the number of true- and
false-positive and true- and false-negative outcomes of
a screening test. To illustrate how the prevalence of a
disease, and the sensitivity and specificity of the
screening test, drive the trade-offs, consider the fol-
lowing hypothetical example. A disease has a preva-
lence of 1%. A screening test designed to detect this dis-
ease has a sensitivity of 95% and a specificity of 90%. If
100,000 individuals are screened, we can expect 950
true-positive outcomes and 9,900 false-positive out-
comes. The ratio of true- to false-positive outcomes is
1:10, which implies that for every case detected, ten
subjects will undergo further unnecessary testing,
experience associated anxiety, and induce costs to the
health care system and society.
These calculations are for one disease. In screening
for more than one disease, the possibility of a false-
positive test result applies to each disease and/or
organ screened, which dramatically increases the like-
lihood that an individual will have at least one false-
positive result. Analogously, the false-negative rate
applies to each disease too, which increases the likeli-
hood that an individual will have at least one false-neg-
ative result. For example, assume that the same hypo-
thetical screening test, with the same sensitivity and
specificity, is designed to simultaneously detect anoth-
er disease with the same prevalence. The overall sensi-
tivity becomes 90% (95% × 95%) and the overall speci-
ficity 81% (90% × 90%). With this screening program
there will be 1,800 true-positive outcomes and 18,600
false-positive outcomes.
Evaluation of CT screening
Bearing in mind the possible positive and negative out-
comes of screening, we can now list the prerequisites
for a cost-effective screening program (see “Prerequi-
sites for screening”) and the parameters that should be
considered in evaluating a screening program (Table 1).
Whereas RCTs are absolutely crucial in defining the
benefits of screening, a preliminary estimate of the
costs and benefits that can be expected with screening
can be derived by simulation models. Models are also
very useful adjuncts to RCTs in extrapolating long-
term outcomes from short-term results and in esti-
mating the associated costs of the diagnostic workup,
therapeutic procedures, follow-up, and caregiving.
Such models for screening generally demonstrate a very
small mean gain in effectiveness, but one should keep
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in mind that whereas the majority of the cohort stud-
ied will experience no difference in effectiveness, a very
small proportion of the cohort will experience a large
gain. Simulation models are necessarily based on sim-
plifying assumptions to make the problem tractable.
Nevertheless, they synthesize and integrate the cur-
rently available evidence into one consistent whole,
which can guide decision making. In addition, they
provide the opportunity to explore the effect of uncer-
tainty in the estimated parameters and variability in the
screened population by performing sensitivity analysis.
Furthermore, such analyses can help define research
priorities by estimating the value of performing anoth-
er study to obtain more information.
Screening for coronary calcium
Coronary calcification can be considered the cumula-
tive effect of exposure to cardiovascular risk factors
and therefore an overall indicator of atherosclerotic
disease. The prevalence and incidence of atheroscle-
rotic disease are high, especially in the elderly. Approx-
imately 35% of all deaths in the Western world are due
to cardiovascular disease, and in a prospective cohort
study in The Netherlands, more than half of all sub-
jects over 55 had calcified coronary arteries, an indica-
tion of atherosclerotic disease (2).
Published evidence suggests that coronary calcium
detected by EBCT is predictive of CHD events in asymp-
tomatic populations. The relative risk for a CHD event
in the presence of calcified coronary arteries is substan-
tial. A systematic review (3) demonstrated an increased
risk for the combined outcome of nonfatal MI, death,
or revascularization in individuals with calcium levels
above the population median level. The studies pub-
lished to date, however, are limited by various method-
ological issues, making it difficult to assess whether the
use of EBCT has incremental value compared to using
the traditional risk indicators only. Well-performed
prospective studies are required to determine the real
value of CT screening of coronary calcium.
Imaging technology is constantly advancing. In the last
2–3 years MDCT has become available, and it is virtually
replacing EBCT for fast scanning. MDCT is responsible
for stimulating the marketing of CT screening. Sensitiv-
ity, specificity, and reproducibility of MDCT for the
detection of coronary calcium have been shown to be
higher than those for EBCT (4, 5), implying that MDCT
is a promising technique, but its effectiveness in screen-
ing programs has not yet been proven.
One problem with the use of CT for the identification
of coronary calcifications is the presence of incidental
findings. With cardiac CT, only 30% of the lungs is
imaged, and the population is not restricted to current
or former smokers. Therefore, the prevalence of malig-
nant lung nodules is much lower than in CT lung can-
cer screening cohorts. One study reported that 53% of
1,812 patients who underwent cardiac CT had non-
coronary and extracoronary incidental findings but
only 0.2% had malignant disease (6).
There are many alternative screening methods for the
identification of subjects at high risk for atheroscle-
rotic disease. These methods determine traditional risk
indicators including blood pressure, smoking history,
lipid levels, body weight, and family history, as well as
less traditional indicators such as homocysteine; ankle-
brachial index (the ratio of the systolic blood pressure
measured at the ankle to that measured at the arm);
evidence of prior infarction or ischemia, measured by
ECG; C-reactive protein; and carotid intima thickness,
measured with ultrasound. Since this is an area of
active research, it is highly likely that new risk indica-
tors will be found in the future.
Patients identified with atherosclerotic disease and at
high risk for a cardiovascular event can be treated effec-
tively with aspirin therapy, cholesterol-lowering agents,
and, if the patient is hypertensive, with antihyperten-
sive drugs. Findings in a CT scan may also motivate
lifestyle changes. Aspirin, at a dosage of 75 mg/d, has
been evaluated for primary prevention and shown to
significantly reduce the number of MIs and all-cause
mortality (7). Aspirin use is, however, associated with
an increased risk of hemorrhagic stroke and an
increased risk of major gastrointestinal bleeding. Of all
the cholesterol-lowering agents, statins are currently
the most used. A meta-analysis of five large random-
ized trials of long-term statin treatment compared with
placebo, involving 30,817 participants with a mean
duration of treatment of 5.4 years, demonstrated that
statins reduced major coronary events (i.e., MI and
CHD-associated death) as well as all-cause mortality
(8). A systematic review and meta-analysis of antihy-
pertensive therapy (9) demonstrated that initial low-
dose thiazide therapy was the most effective. Compared
with placebo, low-dose thiazide therapy reduced CHD
events, stroke, and all-cause mortality.
A number of RCTs of coronary calcium screening with
EBCT are underway that will assess the impact of EBCT
information (10) and the effect of atorvastatin plus vita-
Prerequisites for screening 
The disease must be common and have substantial morbidity and/or mortality
The screening test must be acceptable, feasible, and accurate for the detection of subclinical disease
Curative potential must exist primarily at early disease stages
Early detection must result in improved patient outcomes
Sufficient resources must exist for screening, diagnosis, and therapy
In screening a (selected) population, there must be a favorable trade-off between risks, benefits, and costs
mins C and E therapy on patients with EBCT-detectable
coronary calcification (11). In the meantime, we have to
base our judgments on published cost-effectiveness
analyses. One cost-effectiveness analysis of EBCT
screening for the identification of patients with coro-
nary calcification suggests that statin therapy is highly
cost-effective and that EBCT screening may be helpful
in defining which subjects should receive statins (12)
(Table 2). The analysis was, however, based on the
assumption that coronary calcification on EBCT is cor-
related with arteriographic luminal narrowing and that
luminal narrowing predicts coronary events. This
ignores the fact that many coronary events are caused
by noncalcified vulnerable plaque, which will not be
identified by either CT or arteriography. A more con-
vincing argument could be made if the cost-effective-
ness of screening were to be modeled based on the
results of prospective studies predicting coronary events
in relation to the calcium score and with an RCT of CT
screening. Furthermore, if advances in CT technology
permit vulnerable plaques to be reliably identified, the
prediction of future events could potentially be
improved. Finally, programs designed to encourage
lifestyle changes, interventions for smoking cessation,
monitoring and treatment of blood pressure and lipid
levels, and perhaps even universal treatment with statins
and/or aspirin above a certain age may be more cost-
effective than CT screening and should be considered as
alternatives when CT screening programs are evaluated.
Screening for lung cancer
The prevalence of lung cancer is a little over 1% in cur-
rent and former smokers, and the annual incidence lies
between 0.4% and 0.7% (13, 14). The overall 5-year sur-
vival of patients diagnosed with lung cancer is 13%.
Five-year survival of treated localized disease is higher,
and screening has therefore focused on attempting to
diagnose lung cancer in its localized stage.
Published prospective uncontrolled cohort studies of
high-risk current or former smokers suggest that heli-
cal CT can diagnose lung cancer in an early stage,
which would advance the time of diagnosis to a time
when the cancer is potentially curable (13). All studies
were performed in high-risk populations of current or
former smokers. In all studies, indeterminate nodules
that required additional diagnostic procedures and fol-
low-up were detected in a large number of individuals
(12–51% of individuals in the base-line screening exam-
inations, and 2–13% in the annual repeat examina-
tions). As the distinction between benign and malig-
nant nodules is not reliable based on CT imaging
criteria alone, additional follow-up CT scans are
required to monitor the growth of such nodules. A
biopsy is commonly required to determine the nature
of the lesion, and a wedge resection is sometimes nec-
essary to rule out cancer.
The primary treatment is surgical resection of the
lung cancer. Five-year survival, if the disease is localized,
has been reported to be between 67% and 80%. Only
10–15% of patients currently present with localized dis-
ease. Advocates of CT screening assume that early
detection with screening implies a stage shift from
advanced to localized disease. They further assume that
localized disease is curable. These assumptions ignore
the bias introduced by pseudo–stage shift, lead time,
and length time, as explained earlier.
At present, there are no published RCTs on CT screen-
ing for lung cancer. RCTs have been published that eval-
uated screening with chest x-rays, with or without spu-
tum cytology, but no benefit was demonstrated (15).
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Table 1
Parameters for evaluating screening programs
Disease Prevalence of disease, probability of disease in selected populations at high risk
Annual incidence of disease
Natural history of disease
Screening test Sensitivity and specificity of the screening examination
Radiation-associated risk
Loss in quality of life due to screening test and possible further workup
Complication rate of further diagnostic workup
Proportion of nonadherence to screening program
Alternative screening tests
Treatment Available therapy
Proportion of diagnosed patients that are treatable
Benefit from early treatment, curability, efficacy, quality of life
Complication rate of treatment
RCTs Size
Screening program
Duration of follow-up
Mortality and morbidity reduction
Costs and cost-effectiveness Costs of screening test and further workup
Costs of treatment and follow-up medical care, risk factor modification, lifestyle changes
Costs of informal caregiving, travel and time costs, lost productivity
Evaluation of different screening programs and alternatives to screening
Perspective (societal perspective should be considered)
Effectiveness gained: composite measure that integrates risks, benefits, and quality of life
Incremental costs of screening program
Trade-off of costs and effectiveness: incremental costs per effectiveness gained
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Several RCTs are ongoing or planned, including the
USA National Lung Screening Trial, in which 50,000
subjects are to be randomized; the French Depiscan
trial, randomizing 21,000 subjects; the NELSON trial in
The Netherlands, randomizing 24,000 subjects; and the
LUCAS trial in the United Kingdom, randomizing
40,000 subjects (16). These studies will take 5–10 years
to recruit subjects and to complete necessary follow-
ups, and they are all multimillion-dollar endeavors.
Three cost-effectiveness analyses have recently been
published based on simulation modeling (13, 14, 17).
All three analyses have important limitations. For
example, Marshall et al.’s model (17) included no costs
related to other diseases or to complications resulting
from biopsies, and it excluded increased risk of death
and associated costs from the numerous diseases com-
mon in older smokers, such as cardiovascular disease
and other cancers. Chirikos et al.’s analysis (14) took a
national payers group perspective, used the results
from only one study for sensitivity and specificity esti-
mates of the screening program, did not adjust for
quality of life, and discounted only costs but not effects
(thus favoring screening). Furthermore, Chirikos et al.
(14) did not adjust for any form of bias, and Marshall
et al. (17) provided only a crude estimate of the effect
of lead-time bias. Mahadevia et al. (13) did take possi-
ble lead-time and length bias into account, though only
to a limited extent, and they performed a sensitivity
analysis for pseudo–stage shift bias.
Overall, the analysis by Mahadevia et al. (13) was the
most comprehensive and the most consistent with rec-
ommended standards for cost-effectiveness analyses (13,
18) (Table 2). The analysis evaluated a screening program
with 20 annual helical CT scan screens starting at the age
of 60 in current, quitting, and former smokers and con-
sidered a 20-year time frame. Mahadevia et al. took a
societal perspective (as is recommended), used pooled
estimates from four published prospective cohort stud-
ies of CT screening for lung cancer, adjusted for quality
of life, and discounted for both costs and effects (as rec-
ommended by the US Panel on Cost Effectiveness in
Health and Medicine; ref. 18). The results demonstrated
that CT screening is not cost-effective. The authors con-
cluded, and we agree, that major hurdles — in particular
the incidence of false-positive outcomes — would need
to be overcome before CT screening for lung cancer
could be cost-effective. In fact, it may be more effective
to search for another screening method, such as bio-
markers in sputum (possibly combined with CT as the
second step), or to invest in antismoking programs. The
US Preventive Task Force currently does not recommend
the use of CT to screen for lung cancer in asymptomatic
individuals without a history of cancer.
Screening for colorectal cancer
The lifetime risk of colorectal cancer in the US is 5.6%
(19). An important distinguishing feature of colorectal
cancer in the context of screening for disease is the exis-
tence of a precancerous lesion, namely the polyp.
The fecal occult blood test (FOBT) is commonly
used as the first step in screening for colon cancer,
because it is simple and inexpensive, but it has a low
degree of sensitivity. The double-contrast barium
enema has long been used as the standard imaging
screening test for colorectal cancer. Although earlier
studies reported reasonable sensitivity and specificity,
a recent study of the double-contrast barium enema
reported a sensitivity of 48% for lesions over 1 cm and
a specificity of 85% (20) . This study was, however,
based on a patient population presenting with symp-
toms rather than a screening population and had
methodological problems; it probably yielded an over-
ly pessimistic estimate of the sensitivity of the double-
contrast barium enema. The barium enema is associ-
ated with a low risk of bowel perforation and a low
radiation dose. Colonoscopy has a sensitivity of 95%
and, when combined with histological verification of
any lesions found, an assumed specificity of 100%. It is
associated with a risk of bowel perforation of 1 in
1,000 individuals (19). Sigmoidoscopy is similar but
examines only a limited part of the colon, which has
the highest incidence of cancer. Both double-contrast
barium enema and colonoscopy/sigmoidoscopy are
uncomfortable to the patient, and compliance with
these tests for screening is low.
CT colonography is currently under development.
The reported sensitivity is in the range of 90–94% with
a reported specificity of 72%, and the procedure has vir-
tually no associated risk of bowel perforation (19). Of
note, CT colonography is not part of a regular CT scan;
the patient requires extensive preparation with purga-
tives to cleanse the colon, and retrograde insufflation
with air or carbon dioxide is necessary to distend the
colon. Thus, CT colonography requires more time and
expense than a regular CT scan and is somewhat more
uncomfortable for the patient. Another new, but as-yet
unproven, screening method is a test for colorectal can-
cer biomarkers in patient feces.
Polyps found during screening are precancerous and
need to be removed. Polypectomy can conveniently and
safely be performed during colonoscopy, which is an
advantage of using it as a screening method. If histol-
ogy demonstrates a high-risk polyp, a more intensive
surveillance scheme with colonoscopy is advised. Col-
orectal cancer is surgically resected, and adjuvant
chemotherapy may be given.
Published RCTs of screening for colorectal cancer
have evaluated the FOBT and demonstrated that annu-
al screening reduces cancer incidence and mortality by
20% and 33%, respectively (21). Sigmoidoscopy screen-
ing has also been demonstrated to result in a decrease
in colorectal cancer mortality rates (21). As yet, no
RCTs have been published evaluating colonoscopy,
double-contrast barium enema, or CT colonography.
McMahon et al. compared and reanalyzed the results
of three often cited cost-effectiveness analyses of col-
orectal cancer screening in average-risk populations
(22). In spite of differences across these studies, when
standardized methods were used to reevaluate the stud-
ies, a concordant optimal screening strategy emerged:
double-contrast barium enema every 3 years, or every 5
years accompanied by the FOBT. The incremental cost-
effectiveness ratio was less than $56,000 (US dollars)
per life year saved, which is generally considered cost-
effective. These cost-effectiveness analyses, however,
were performed before publication of the more recent
study of double-contrast barium enema in which sen-
sitivity was reported to be 48% (20). Furthermore, the
authors of these cost-effectiveness analyses did not con-
sider CT colonography. Another cost-effectiveness
analysis, performed from the perspective of the third-
party payer, compared CT colonography to
colonoscopy and to no screening (23) (Table 2). The
results demonstrated that CT colonography was cost-
effective compared with no screening, but not cost-
effective compared to screening with colonoscopy. This
analysis, however, failed to include relevant strategies
that use double-contrast barium enema and the FOBT,
and it used preliminary results of CT colonography;
therefore the reported results may not be meaningful.
All published cost-effectiveness analyses suggest that
screening for colon polyps to prevent colorectal cancer
is cost-effective when compared with no screening (24).
No one strategy, however, can be shown to be consis-
tently better than the others given the currently avail-
able evidence. CT colonography could potentially play
a role, but the high incidence of false-positive outcomes
is still a major hurdle.
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Table 2
Parameters to consider in the evaluation of CT screening programs
Parameters Coronary calcium Lung cancer Colorectal cancer AAA 
to consider (2, 3, 7–12) (13, 14) (19, 21, 23) (25–27, 29)
Disease
Prevalence Depends on definition of disease 1–2% High-risk polyps: 2% 5%
Incidence CHD events: 1–2% annually 0.4–0.7% 0.05% Not available
Age of cohort 55–85 Current and former 50 65–74, male only 
smokers, age-independent
Screening test
Test positive 50% 20% 30% 5%
Sensitivity/specificity 55%/94% First scan: 93%/80% 90–94%/72% ∼100%/∼100%
Repeat scan: 85%/92%
Risk Radiation (1–6 mSv) Radiation Radiation. Very low risk Radiation
of perforation
Further workup None Repeat CTs, biopsy Colonoscopy, biopsy Repeat CT/Ultrasound 
for growth
Nonadherence 5% 6.5% 35% 20%
Alternative tests Blood pressure, lipid levels, Biomarkers in sputum Barium enema, FOBT, Ultrasound
smoking history, ankle-brachial sigmoidoscopy, colonoscopy, 
index, other cardiovascular biomarkers in feces
risk indicators
Treatment
Available therapy Statins, aspirin, Surgical resection Polypectomy, surgery Surgery for AAA ≥ 5.5 cm
antihypertensives
Proportion treatable 100% 50–60% Polyps: 100% ∼100%
Curability/efficacy Risk reduction ∼30% Assumption: stage shift Localized: 5-yr survival 90%; Relative risk of AAA-related 
Metastasized: 5-yr survival 8% death 0.58
Complications Hemorrhage with aspirin Surgical complications Colon perforation Mortality 4%
Randomized PACC, St. Francis USA, France, The Netherlands, None on CT colonography Multicentre Aneurysm  
screening trials Heart Study United Kingdom ScreeningStudy, United  
Kingdom,using ultrasound
Costs (estimates)
Screening test 200–300 300 500 200–300
Further workup None 300–5,000 1,000 200–300
Treatment 500/yr 44,000–67,000 1,500–22,000 11,000
Cost-effectiveness
Program EBCT screening + statins Annual CT, 20 yr, Screen every 10 yr (One-time ultrasound, 
current smokers 65–74 yr; time frame 10 yr)
Perspective Health care system Societal Health care system Health care system
Effectiveness gained 4 events less/1,000 pers-yr 0.04 QALYs 0.05 LYs 0.002 LYs
Incremental costs pp. 1,000 4,600 600 100
Trade-off 200/CHD event avoided 116,300/QALY 11,500/LY 13,000/LY
All costs are shown in US dollars. mSv, millisievert; PACC, Prospective Army Coronary Calcium study; pers-yr, person years of follow-up; pp., per person
screened; LY, life year; QALY, quality-adjusted life year.
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Screening for AAA
In a large randomized study evaluating screening for
AAA, aneurysms of more than 3 cm were detected with
ultrasound in 5% of men aged 65–74 who were under-
going screening (25). The rupture rate of aneurysms
smaller than 5.5 cm is 1% per year, and the risk of rup-
ture increases with the diameter of the aneurysm (26).
Aneurysm rupture can sometimes be treated with
emergency surgery but is generally associated with a
high mortality and morbidity rate.
Ultrasound is a reliable and inexpensive screening
test for detecting AAA. In the majority of individuals,
the aorta can be identified and measured, but some
individuals are very obese or have overlying bowel gas
that precludes adequate ultrasonographic imaging. CT
scanning virtually always provides adequate images
and a reliable measurement of the aorta. Furthermore,
CT, in contrast to ultrasound, is operator independent.
Open elective surgery is indicated for aneurysms
measuring 5.5 cm or more. A larger diameter is used as
a threshold for patients at high risk for perioperative
complications due to comorbidity. Perioperative mor-
tality is, on average, 4–7%, and systemic or remote com-
plications occur in up to 44% of patients (27). A new,
but unproven, therapy — endovascular treatment — in
which a stent graft is placed using a catheter technique
via the common femoral arteries is associated with
lower mortality and complication rates (27) and is
potentially cost-effective (28), but the results during
long-term follow-up are still uncertain.
The Multicentre Aneurysm Screening Study in the
United Kingdom (25) was a population-based ran-
domized controlled screening trial in which 67,800
men aged 65–74 years were randomized to be invited
for abdominal ultrasound for the detection of AAA or
to receive usual care. Aneurysms of 3–4.5 cm were fol-
lowed annually with ultrasound. Aneurysms of 4.5–5.4
cm were subject to ultrasound analysis in 3-month
intervals. Surgery was performed if an AAA of 5.5 cm or
more was detected, if expansion of 1 cm or more per
year occurred, or if the patient developed symptoms.
During follow-up, the risk of aneurysm-related death
in the invited group compared with the control group
was substantially reduced. The benefit of this screening
trial can be extrapolated to screening with CT, as CT
would diagnose AAA with even greater accuracy. The
only disadvantages of using CT would be a very small
risk associated with radiation exposure and a slight
increase in the costs of the screening test.
A cost-effectiveness analysis was performed based on
the results of the Multicentre Aneurysm Screening
Study (29). Over the 4-year period observed, the associ-
ated costs were $45,000 per life year gained and $57,000
per quality-adjusted life year gained, which is consid-
ered cost-effective. When extrapolated to 10 years, the
incremental cost-effectiveness ratio was $13,000 per life
year gained, which is even more favorable.
Although these results apply to ultrasound, screen-
ing for AAA can be done more easily, accurately, and
reliably with CT scanning. The major benefit of CT
scanning compared with ultrasound is its operator-
independence and the superior image quality, especial-
ly in obese patients. If the abdominal aorta were to be
scanned (even if only over a limited part) as part of a
more comprehensive CT scan screening examination,
the screening test’s marginal cost would be very low. To
avoid high follow-up costs, serial follow-up examina-
tions could be performed with ultrasound.
Additional considerations
In this article we have discussed CT screening for the
identification of patients with coronary calcification,
lung cancer, colorectal polyps or cancer, and AAAs.
CT screening has also been advocated to detect
tumors of the liver, kidney, ovary, and other abdom-
inal organs. Prevalence of clinically relevant cancer in
the abdominal organs is extremely low and the pro-
portion of false positives high. On unenhanced CT,
masses are commonly found that require follow-up
with enhanced CT, MRI, and, in some cases, biopsy.
Most masses turn out to be cysts or hemangiomas,
which are benign lesions of no consequence. Fur-
thermore, if one looks very carefully in the kidney
with microsection pathology, one will invariably find
cancer cells (30), but most of these would never devel-
op into clinically relevant cancers. This implies that
overdiagnosis bias is likely to influence reports on
screening for these cancers. Furthermore, there is no
evidence that abdominal tumors can be diagnosed
using CT screening at a curable stage, and no evi-
dence of the cost-effectiveness of CT screening for
abdominal tumors in general.
Although the radiation dosage with MDCT is a con-
cern, the radiation risk from performing a single study
is low. A dose of 100 millisieverts (mSv) is estimated to
cause only 0.004 long-term mutations per cell, a triv-
ial addition to the one mutation per cell per day that
results from natural processes (31). Biological defense
mechanisms ensure an adaptive response of cells to
low-level radiation by stimulating production of repair
enzymes and an increased immune response. Moni-
toring of 96,000 radiation workers in the US, the Unit-
ed Kingdom, and Canada found no indication of
excess risk for doses less than 400 mSv (31). The inci-
dence of breast cancer in Canadian women exposed to
x-ray fluoroscopy for tuberculosis suggests no excess
risk for doses less than 200 mSv, and data on the inci-
dence of lung cancer in these women suggests that
there is no excess risk for doses less than 1,000 mSv
(31). Assuming that a CT scan is associated with a radi-
ation dose of between 2 and 6 mSv, we can safely con-
clude that if a scan were to be performed every 5 years
starting at, for example, age 50, we would not need to
worry about the radiation risk. If, on the other hand, a
scan were to be performed every year and additional
follow-up scans were performed in a large proportion
of patients with abnormal findings, the radiation dose
is a cause for concern.
Conclusions
To date, it remains unproven that CT screening is ben-
eficial, especially in the low-risk population. RCTs cou-
pled with cost-effectiveness analyses are needed. The
evidence available thus far suggests that the mean gain
in life expectancy is very small, that the cost to the
health care system and society is enormous, and that
the potential harm to the individual is real.
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